The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...
The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone ...
The FDA granted a fast track designation to ALE-P02 for patients with CLDN1-positive squamous solid tumors. The FDA granted ...
Clinicians should consider a rapid taper approach for patients with cancer who exhibit repeated signs of opioid misuse, an ...
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
Subcutaneous pembrolizumab plus chemotherapy was noninferior to IV pembrolizumab plus chemotherapy in treatment-naïve non-small cell lung cancer. Pembrolizumab (Keytruda) and berahyaluronidase alfa ...
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
While bispecific antibodies tend to be well-tolerated for patients with multiple myeloma, there are still adverse effects clinicians should discuss with their patients. The use of bispecific ...
Mirdametinib led to confirmed responses and meaningful pain and health-related quality of life improvements in both children and adults with neurofibromatosis type 1-associated PNs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback